leadf
logo-loader
viewHelix BioPharma Corp.

Helix Biopharma shares rise despite posting $1.9 million loss in fiscal 2Q

The company is spending $1.3 million on research and development for its innovative cancer therapy

Lab tech looking in a microscope
The biopharmaceutical company is currently conducting Phase I trials for its cancer-fighting drug

Helix Biopharma Corp (TSE:HBP) pushed ahead its research-and-development spending in the fiscal second quarter of 2019, despite recording a net loss of $1.9 million, according to financial results released Monday.

The company posted a net loss of $1.9 million, or $0.02 loss per common share, in the three months ended January 31, compared with a $2.6 million, or $0.03 loss, a year earlier.

Shares of Helix rose $0.03 on Monday to $0.54, a gain of 5.9%.

READ: Leap Therapeutics shares pop thanks to promising trial for cancer drug DKN-01

Helix, a clinical-stage biopharmaceutical company that is developing innovative therapies for cancer treatment, spent $1.3 million in research and development in fiscal 2Q and $2.3 million for the six-month period, the bulk of which was directed toward its L-DOS47 technology, which promises to act upon naturally-occurring substances in the human body to treat cancer.

The company spent $788,000 in the quarter, primarily on its Phase 1 clinical study in the US. It also conducting clinical studies in Poland, Ukraine and Hungary.

The Polish subsidiary, which is focusing on the V-DOS47 clinical program, spent $102,000 and $232,000 over the three-month period ending January 2019 and 2018, respectively. Grant-funding for the V-DOS4 program is the result of an agreement with the Polish National Centre for Research and Development.

Helix also reported a working capital deficiency of $2 million, a shareholders’ deficiency of $1.7 million and a deficit of $167 million. The company’s cash reserves of $306,000 are insufficient to meet its working capital and capital expenditures for the next 12 months, as well as its R&D expenditures, it reported.

--Contact Angela Harmantas at angela@proactiveinvestors.com

--Follow her on Twitter @AHarmantas

Quick facts: Helix BioPharma Corp.

Price: 0.41 CAD

TSX:HBP
Market: TSX
Market Cap: $54.5 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Helix BioPharma Corp. named herein, including the promotion by the Company of Helix BioPharma Corp. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Helix BioPharma extends Moffitt cancer center collaboration to further...

Helix BioPharma Corp (TSX:HBP) (OTCMKTS:HBPCF) CEO Heman Chao tells Proactive the immuno-oncology focused biotech has extended its collaboration with the Florida-based Moffitt Cancer Center for a further year, building on the pair's progress so far. Chao says Helix and Moffitt have already...

on 13/8/20

2 min read